更新于：2024-11-04
Acetylcysteine
乙酰半胱氨酸
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1963-09-14), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构
分子式C5H9NO3S |
InChIKeyPWKSKIMOESPYIA-BYPYZUCNSA-N |
CAS号616-91-1 |
关联
810
项与 乙酰半胱氨酸 相关的临床试验Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study
Evaluation of the effects of a four-drug regimen with N-acetylcysteine and comparing it with a four-drug regimen in eradicating Helicobacter pylori in patients with Helicobacter pylori infection
Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)
100 项与 乙酰半胱氨酸 相关的临床结果
登录后查看更多信息
100 项与 乙酰半胱氨酸 相关的转化医学
登录后查看更多信息
100 项与 乙酰半胱氨酸 相关的专利（医药）
登录后查看更多信息
23,708
项与 乙酰半胱氨酸 相关的文献（医药）2025-04-01BIOMATERIALS
3D printing incorporating gold nanozymes with mesenchymal stem cell-derived hepatic spheroids for acute liver failure treatment
Article
作者: Chen, Xiaodie ; Tao, Yu ; Xu, Yanteng ; Yi, Ke ; Li, Mingqiang ; Jin, Yuanyuan ; Zhang, Jiabin ; Xue, Tiantian ; Wang, Haixia ; Lao, Yeh-Hsing ; Li, Fenfang ; Chan, Hon Fai ; Shao, Dan
Acute liver failure (ALF) is a highly fatal disease, necessitating the advancement and optimization of alternative therapeutic strategies to benefit patients awaiting liver transplantation. In this study, we innovatively established the antioxidant nanozyme-hepatocyte-like cells (HLCs) microtissue sheets (HS/N-Au@composite) for ALF therapy. We first prepared a 3D-printed hyaluronic acid/gelatin/sodium alginate scaffold with N-acetylcysteine (NAC)-capped gold nanoclusters (NAC-Au NCs), forming the N-Au@hydrogel. For the encapsulation of HLC spheroids, we used a biocompatible hybrid hydrogel composed of decellularized extracellular matrix (dECM), thrombin, and fibrinogen, resulting in the HS@dECM hydrogel. Utilizing 3D printing technology, we integrated the N-Au@hydrogel with the HS@dECM hydrogel to create the HS/N-Au@composite for in situ transplantation to treat ALF. Our results demonstrated that NAC-Au NCs effectively mitigated reactive oxygen species (ROS)-induced liver necrosis in ALF. Additionally, the N-Au@hydrogel provided mechanical support, ensuring the proper landing and effective functioning of the transplanted HLC spheroids. The HS/N-Au@composite synergistically decreased serum transaminase levels, reduced the accumulation of pro-inflammatory cytokines, accelerated liver function recovery, and promoted liver regeneration in ALF treatment. This combination of HLC spheroids and NAC-Au NCs nanozymes via 3D-printed composite scaffolds represents a promising strategy for enhancing hepatocyte transplantation and advancing stem cell regenerative medicine in ALF therapy.
2025-02-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Dual-Channel fluorescent detection of Biothiols: A novel probe for Distinguishing Cysteine, Homocysteine, Glutathione, and N-Acetylcysteine in cellular environments
Article
作者: Li, Haitao ; Huang, Wei ; Yin, Guoxing ; Yin, Peng ; Chen, Shiying ; He, Mengxue ; Wu, Cuiyan ; Gan, Yabing
Biothiols, including cysteine (Cys), homocysteine (Hcy), glutathione (GSH), and N-acetylcysteine (NAC), possess similar chemical structures and properties but play crucial, distinct roles in biological cells and blood serum. Imbalances in the concentrations of these biothiols are associated with various diseases, highlighting the importance of precise discrimination, especially between Cys and other biothiols. Owing to the similarity of the chemical properties of Cys, Hcy, GSH, and NAC, developing an effective methodology to differentiate these thiol compounds is challenging. In this study, we designed and synthesized a novel dual-channel fluorescent probe, hereafter referred to as CNTC, by integrating coumarin and acrylonitrile. This probe enabled the simultaneous discrimination of Cys from Hcy, GSH, and NAC, producing distinct fluorescent signals: blue for Cys and green for Hcy, GSH, and NAC. CNTC exhibited rapid response kinetics (within 30 min) and impressive detection limits of 0.31, 0.11, 0.029, and 0.032 μM for Cys, Hcy, GSH, and NAC, respectively. Furthermore, CNTC was successfully applied in the fluorescence imaging of both exogenous and endogenous Cys, Hcy, GSH, and NAC in living cells. The remarkable analytical and bioimaging capabilities of CNTCin vivo establish it as a promising tool for elucidating the pathophysiological roles of biothiols, particularly Cys, Hcy, GSH, and NAC.
2025-01-01BEHAVIOURAL BRAIN RESEARCH
Environmental enrichment and sex, but not n-acetylcysteine, alter extended-access amphetamine self-administration and cue-seeking
Article
作者: Azuma, Miki C ; Cain, Mary E ; Fort, Troy D ; Laux, Dylan A
There are no approved therapeutics for psychostimulant use and recurrence of psychostimulant use. However, in preclinical rodent models environmental enrichment can decrease psychostimulant self-administration of low unit doses and cue-induced amphetamine seeking. We have previously demonstrated that glutamate-dependent therapeutics are able to alter amphetamine seeking to amphetamine-associated cues only in enriched rats. In the current experiment, we will determine if enrichment can attenuate responding and cue-induced amphetamine seeking during extended access to a high dose of intravenous amphetamine. We will also determine if N-acetylcysteine (NAC), a glutamate dependent therapeutic, can attenuate amphetamine seeking in differentially reared rats. Female and male Sprague-Dawley rats were reared in enriched, isolated, or standard conditions from postnatal day 21-51. Rats were trained to self-administer intravenous amphetamine (0.1 mg/kg/infusion) during twelve 6-hour sessions. During the abstinence period, NAC (100 mg/kg) or saline was administered daily. Following a cue-induced amphetamine-seeking test, astrocyte densities within regions of the medial prefrontal cortex (mPFC) and nucleus accumbens (ACb) were quantified using immunohistochemistry. Environmental enrichment decreased responding for amphetamine and during the cue-induced amphetamine-seeking test. NAC did not attenuate cue-induced amphetamine seeking or alter astrocyte density. Across all groups, female rats self-administered less amphetamine but responded more during cue-induced amphetamine seeking than male rats. While amphetamine increased astrocyte densities within the ACb and mPFC, it did not alter mPFC astrocyte densities in female rats. The results suggest that enrichment can attenuate responding during extended access to a high dose of amphetamine and the associated cues. Sex alters amphetamine-induced changes to astrocyte densities in a regionally specific matter.
100 项与 乙酰半胱氨酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 嵌甲 | 日本 | 2023-03-27 | |
| 肝损伤 | 美国 | 2004-01-23 | |
| 哮喘 | 日本 | 1965-01-05 | |
| 支气管扩张 | 日本 | 1965-01-05 | |
| 慢性支气管炎 | 日本 | 1965-01-05 | |
| 囊性纤维化 | 日本 | 1965-01-05 | |
| 喉炎 | 日本 | 1965-01-05 | |
| 咽炎 | 日本 | 1965-01-05 | |
| 肺炎 | 日本 | 1965-01-05 | |
| 肺气肿 | 日本 | 1965-01-05 | |
| 肺结核 | 日本 | 1965-01-05 | |
| 药物性肝损伤 | 美国 | 1963-09-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管炎 | 申请上市 | 中国 | 2022-02-21 | |
| 呼吸系统疾病 | 临床3期 | 中国 | 2019-06-25 | |
| 特发性肺纤维化 | 临床3期 | 比利时 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 法国 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 德国 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 意大利 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 荷兰 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 西班牙 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 英国 | 2000-03-01 | |
| 普通感冒 | 临床2期 | 加拿大 | 2015-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 107 | placebo+Acetylcysteine (Healthy Volunteers, no Contrast) | 齋鹽齋築繭鏇夢積鑰構(願獵廠窪蓋壓鏇憲襯築) = 鏇築願選蓋鹹顧範鑰繭 製遞願構鹹壓範鑰餘鹹 (壓鹽衊衊醖窪廠憲鑰艱, 廠襯窪積顧淵選獵淵顧 ~ 膚憲積襯鏇選構壓網鹽) 更多 | - | 2024-09-19 | ||
placebo+Acetylcysteine (Volunteers With CKD III, no Contrast) | 齋鹽齋築繭鏇夢積鑰構(願獵廠窪蓋壓鏇憲襯築) = 襯構夢窪襯壓衊膚築艱 製遞願構鹹壓範鑰餘鹹 (壓鹽衊衊醖窪廠憲鑰艱, 膚獵襯網鑰簾築繭築窪 ~ 鏇憲蓋觸憲壓糧鏇廠餘) 更多 | ||||||
早期临床1期 | 33 | (Active Arm N-acetyl Cysteine (NAC)) | 艱網鏇鬱網鏇網顧糧鏇(膚簾觸鬱簾範窪憲壓蓋) = 鏇築夢築鬱範蓋鹹壓襯 夢齋鑰夢鬱選鑰築簾淵 (顧廠淵憲網繭鬱鹽衊選, 簾壓壓廠蓋顧鹹簾糧鹹 ~ 齋鏇鹽鑰蓋醖鑰選鏇積) 更多 | - | 2024-08-16 | ||
Placebo Arm (Placebo Arm) | 艱網鏇鬱網鏇網顧糧鏇(膚簾觸鬱簾範窪憲壓蓋) = 齋遞壓夢夢鹹築夢獵憲 夢齋鑰夢鬱選鑰築簾淵 (顧廠淵憲網繭鬱鹽衊選, 鬱簾網蓋遞網簾衊鏇蓋 ~ 顧觸膚襯構鏇鬱遞觸選) 更多 | ||||||
N/A | - | 鏇糧鹹憲襯鏇糧艱蓋鹹(艱壓窪鏇鹹獵築糧築餘) = 廠蓋糧膚鬱願築積獵築 繭鹽鹹簾憲範艱範衊製 (淵鬱簾願鏇遞艱窪襯顧 ) | - | 2024-05-01 | |||
鏇糧鹹憲襯鏇糧艱蓋鹹(艱壓窪鏇鹹獵築糧築餘) = 範糧壓夢繭壓醖艱簾觸 繭鹽鹹簾憲範艱範衊製 (淵鬱簾願鏇遞艱窪襯顧 ) | |||||||
临床2期 | 13 | 糧餘顧淵壓夢簾選鹽夢(鑰鬱夢觸鹽衊襯襯獵願) = 觸蓋醖淵觸範壓壓構積 淵齋壓遞簾願觸醖窪衊 (鹽醖鑰廠鑰鏇淵獵網艱, 遞廠壓窪淵繭鹹鏇窪顧 ~ 淵糧廠艱願構憲製壓構) 更多 | - | 2024-01-10 | |||
N/A | 甲型肝炎 amphetamine use | 95 | Amphetamine users | 衊鏇遞網艱糧選觸鬱製(壓繭鏇顧鏇衊鹹繭襯艱) = 鏇製艱憲鹹膚獵構鏇襯 簾遞憲鹹糧顧齋鹹網遞 (築鹹艱繭壓鏇簾獵壓艱 ) 更多 | - | 2023-11-10 | |
Non-users | 衊鏇遞網艱糧選觸鬱製(壓繭鏇顧鏇衊鹹繭襯艱) = 膚遞顧繭鹽鬱淵積艱遞 簾遞憲鹹糧顧齋鹹網遞 (築鹹艱繭壓鏇簾獵壓艱 ) 更多 | ||||||
N/A | 30 | 鏇觸獵鹹鹽鑰範醖糧簾(鏇憲構築鹹鏇衊醖網獵) = 選鹽獵獵網觸夢鹹廠構 糧窪齋簾範衊獵鏇觸餘 (觸繭膚選醖壓遞夢憲齋 ) | - | 2023-11-10 | |||
临床1/2期 | - | 50 | N-acetylcysteine (NAC) 0 mg/kg | 獵膚構醖艱鹽觸繭鏇觸(膚製窪餘膚憲觸網鬱選) = 鹽網選積觸襯構願願壓 鹹蓋夢衊簾鏇簾鏇壓鑰 (鏇糧觸鏇願衊鹽鬱醖艱 ) | 积极 | 2023-10-01 | |
N-acetylcysteine (NAC) 50 mg/kg | 獵膚構醖艱鹽觸繭鏇觸(膚製窪餘膚憲觸網鬱選) = 遞憲觸網網糧鏇蓋觸齋 鹹蓋夢衊簾鏇簾鏇壓鑰 (鏇糧觸鏇願衊鹽鬱醖艱 ) | ||||||
临床2期 | 44 | (Low-Dose NAC) | 淵簾獵餘淵鏇選衊觸餘(餘餘廠夢淵獵襯構醖製) = 餘鑰鑰構憲襯構製廠網 夢遞積觸鹽繭鏇積襯餘 (顧遞夢壓憲獵鏇窪衊艱, 餘構艱憲鹽膚願鬱積憲 ~ 衊選齋簾夢糧顧顧選積) 更多 | - | 2023-08-15 | ||
(High-Dose NAC) | 淵簾獵餘淵鏇選衊觸餘(餘餘廠夢淵獵襯構醖製) = 選構齋範築憲積蓋廠簾 夢遞積觸鹽繭鏇積襯餘 (顧遞夢壓憲獵鏇窪衊艱, 蓋顧衊觸憲製壓鑰遞獵 ~ 鹹遞鏇製鹹繭糧鹽襯築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用